MariMed (MRMD): The $160M Brand Taxed Into a 7-Cent Stock
🎙 Listen — Q&A podcast
The seven-cent brand house that the tax code broke
RoboSystems initiating coverage · Cannabis · Source filing: FY2025 10-K (filed March 12, 2026) + Q1 FY2026 10-Q (filed May 14, 2026). All figures verified live from the SEC XBRL graph via RoboSystems unless attributed otherwise. Not investment advice. No price target.
1. The Hook
MariMed did $159.8 million in revenue last year — a company record, its twenty-fifth straight quarter of positive adjusted EBITDA, with 41% non-GAAP gross margins and a #1-selling edible across four states. It reported a $14.5 million net loss. The stock trades at about seven cents.
Here is why those facts coexist. Under Section 280E of the federal tax code, a cannabis company cannot deduct normal operating expenses, so it is taxed on gross profit instead of net profit. In 2023, 2024, and 2025 MariMed lost money before tax every single year — pretax losses of $6.6M, $4.0M, and $10.9M — and still booked $9.4M, $8.2M, and $3.6M of income tax. Twenty-one million dollars of tax on twenty-one million dollars of pretax losses. The company was taxed as if it were profitable in the exact years it wasn't. And it has largely stopped paying: $27 million of unpaid income tax now sits on the balance sheet against $8.9 million of cash, while the IRS audits its 2022 return. That is the whole MariMed story in one paradox — a genuinely good little operating business wearing a tax code written for drug traffickers.
2. Company Snapshot
MariMed is a vertically integrated multi-state cannabis operator headquartered in Norwood, Massachusetts, trading on the OTCQB as MRMD. Founded in 2014 by Bob Fireman and Jon Levine as a medical-cannabis company — the name is shorthand for "marijuana medicine" — it cultivates, manufactures, and sells branded products: Betty's Eddies fruit chews, Nature's Heritage flower and vapes, Vibations drink mix, Bubby's Baked, InHouse gummies. It runs 13 Thrive dispensaries and seven cultivation/production facilities (526K sq ft) across six plant-touching states — Massachusetts, Illinois, Maryland, Delaware, Ohio, and Missouri — and pushes its brands into additional states (Pennsylvania, New York, Maine) through an asset-light licensing model that books royalty-style revenue with little capital and no plant-touching 280E exposure there; management counts nine states, 660+ wholesale accounts, and $113M) because of debt.900 employees in all. Importantly, it owns most of its real estate, so the debt is mortgages against hard assets. FY2025 revenue split roughly 56% retail ($89.0M) and 44% wholesale ($69.6M). This coverage is built on the FY2025 10-K and the Q1 FY2026 10-Q. Unlike the billion-dollar MSOs, MariMed is a Tier 2 name — a brand-and-wholesale house with a microcap equity ($30M market cap) sitting on top of a much larger enterprise value (
3. The Financial Story
Start with what's actually working, because the headline net loss hides it. MariMed has produced positive adjusted EBITDA for twenty-five consecutive quarters — over six years — but the level tells the boom-bust story plainly: adjusted EBITDA peaked at $42.5M in 2021, then stepped down to $31.9M, $24.6M, $19.3M, and $16.9M in FY2025 as the cycle unwound and wholesale prices compressed. Even at that trough it's a 10.6% margin in a sector where most peers post negative EBITDA. It generated $7.7M of operating cash flow and roughly $6.5M of free cash flow after a frugal $1.2M of capex. Its brands win shelf: Betty's Eddies was the top-selling edible across Illinois, Massachusetts, Maryland, and Delaware combined, it's the #1 wholesaler in Delaware, and Illinois wholesale grew 25% quarter over quarter into Q1. This is not a distressed roll-up. It's a real consumer-products business with positive cash generation and no boom-era impairment scar — goodwill actually rose (to $24.0M from $15.8M) on tuck-in acquisitions, the opposite of the multi-billion-dollar write-offs that gutted Verano and the other megadeal MSOs.
Now the damage. The line between adjusted EBITDA and GAAP net loss is almost entirely two things: 280E tax and interest. Operating income collapsed from $20.4M in 2022 to $14.4M in 2023 to $2.6M in 2024 to a $2.8M operating loss in 2025 — the sector-wide price compression and the cost of standing up new adult-use markets (Ohio, Delaware) eating into a thin-margin model. Layer on $7.5M of interest (4.7% of revenue) and the 280E tax, and a company that makes money at the EBITDA line loses money at the bottom line. The non-GAAP net loss — which strips one-time items — was only $2.9M; the GAAP loss was $14.5M. The gap is the tax code.
The single most important number is the tax line, and it tells a story most coverage misses. From 2022 through 2025 MariMed booked $27.1 million of cumulative income tax expense on cumulative pretax income of roughly negative $1.9 million. A normal business breaking even over four years pays almost nothing; MariMed was charged $27M. The tax footnote makes the distortion even starker than the face of the income statement: the 280E adjustment alone added $10.2M to the FY2025 provision — and ran to a remarkable 240% of pretax income in FY2024 — so the relatively modest $3.6M net provision understates the true drag, lower only because valuation-allowance and uncertain-tax-benefit movements offset part of it. But watch the cash: income taxes actually paid fell from $14.6M in 2022 to $6.4M to $0.7M to a small net refund in 2025. MariMed stopped writing the checks. It joined the group of operators reclassifying their 280E bill into an "uncertain tax position" — accruing the expense but disputing the obligation — and in late 2025 it announced it will file going forward claiming a 280E exemption outright, expecting savings in the "millions." The result is a $27.0M accrued income-tax liability at year-end (up from $21.9M), classified as current, against $8.9M of cash — and it kept climbing, to roughly $29.6M by Q1 FY2026, compounding by about each quarter's tax accrual. The IRS is already auditing the 2022 year, and in a June 2024 bulletin told the industry that amended-return refund claims "are not entitled to a refund."
So the honest read on cash flow versus GAAP: yes, MariMed's positive operating cash flow is the better health signal than its GAAP loss — the standard cannabis point. But here the positive cash flow is flattered by simply not paying the tax it's booking. Strip that out and the underlying business is closer to breakeven on cash, with a ~$30M deferred bill that becomes very real if the dispute goes the wrong way. It already shows in the working capital: on a GAAP basis MariMed's working capital is slightly negative (about –$3.0M at Q1), entirely because that ~$30M of taxes payable sits in current liabilities — exclude the disputed tax and "operating" working capital is a healthy $33.8M. That tension — good operator, dangerous balance-sheet overhang — is the whole investment question.
4. Catalyst Scenarios — How the Math Changes
280E relief — but mind the split. This is where MariMed is genuinely different from the medical-heavy bellwethers, and where most templated cannabis analysis would get it wrong. The April 2026 rescheduling lifted 280E for medical income only. But roughly 80% of MariMed's retail revenue is adult-use, plus a large wholesale book — only about 20% of Q1 retail sales were medical. So the relief that's already law barely touches MariMed: the medical slice locks in a small, immediate benefit, but Q1 FY2026 still carried $2.65M of tax on a $1.1M pretax loss — a –238% effective rate — and management explicitly states it did not yet record any benefit from the April 23, 2026 medical rescheduling in that quarter "due to the timing." So even the small medical-slice relief is still ahead of the reported numbers; the first visible benefit should land in the Q2 FY2026 tax line. MariMed is a "needs the broad switch" name. If a broad Schedule III order removed 280E from adult-use too, the recurring $3–8M annual tax drag on a thin-margin business largely disappears — the difference between a company that bleeds cash and one that compounds it — and the ~$30M accrued liability, more than half of the company's $50M equity, could be written back rather than paid. That balance-sheet swing, not a single year's EPS, is the real prize for MariMed.
The pro forma, stated honestly. Apply a normal posture to FY2025: remove the $3.6M of tax and the net loss narrows from $14.5M to about $10.9M. MariMed does not flip to a fat GAAP profit the way Trulieve or Green Thumb would — its problem is partly operating, not only tax. The power of relief here is cash and the balance sheet: free cash flow could roughly double from ~$6.5M toward $12–15M as the cash tax drag ends, and a ~$30M contingent liability either evaporates or gets resolved. On a $30M market cap, those are enormous numbers.
Consolidation — the cleanest angle. MariMed is exactly the kind of name that gets bought. Enterprise value is only ~$113M, it has durable branded products with real shelf position (Betty's Eddies, Nature's Heritage), positive EBITDA, and a tidy six-state footprint with limited-license exposure in Delaware and Maryland. For a larger MSO filling out the Midwest/Northeast, or a CPG or beverage entrant wanting an instant edibles brand — and note the CPG pedigree: the chief commercial officer who co-created Betty's Eddies spent twenty years at the Boston Beer Company — MariMed is a cheap, clean tuck-in. The catch is the ~$30M tax overhang and the debt — a buyer prices the liability, so the equity premium depends on how the 280E dispute resolves. MariMed is a target, not a buyer; it lacks the balance sheet to be a consolidator. Two real-world updates sharpen the picture. First, MariMed's own expansion is increasingly asset-light: instead of buying plant-touching operations, it licenses its brands into new states — a Bronx processing kitchen is under construction in New York, Pennsylvania product approval is pending, Maine distribution is expanding — generating revenue with little capital and no fresh 280E exposure. Second, Massachusetts just raised its dispensary cap from three to six per operator, and management says it's actively hunting stores in its home market. But be honest about the pace: the CEO concedes rescheduling has not yet changed M&A or banking inbounds — banks and card networks still treat the company as if nothing changed — so the consolidation thesis is real but not yet in motion.
Interstate commerce and hemp. MariMed's wholesale brand engine is the asset that would travel best if interstate commerce ever opened — Betty's Eddies is already a multi-state #1 edible built state by state behind the border wall. And the November 2026 intoxicating-hemp ban removes a gray-market competitor to its licensed edibles and beverages, a modest net positive in its adult-use states.
5. Valuation — What It's Worth If It's a Normal Business
Today MariMed trades around $0.076 — roughly 0.7x EV/revenue and about 6.7x EV to FY2025 adjusted EBITDA of $16.9M, cheaper on sales than the Tier 2 average (1.2x) and near the low end of the cannabis comp set. The market is pricing the base case: 280E persists, the $27M tax bill is a real liability, growth is modest, and a Schedule-I OTC microcap deserves a punishing discount rate.
Two lenses, both framed as implied value under stated assumptions — not a target. First, a scenario DCF. In a base case — 280E stays, an elevated ~16–18% WACC for an OTC Schedule-I name, ~2–3% terminal growth, and ~$6–8M of annual free cash flow that's partly a function of deferring tax — the implied enterprise value lands not far from today's ~$113M. The market is roughly fair on the status quo. In a rescheduling case — broad 280E removal from year one, free cash flow stepping toward $12–15M, a lower risk premium as the existential tax risk fades, and the accrued liability resolved — the same model supports a materially higher enterprise value.
Second, a cross-sector re-rating. Cannabis trades at depressed EV/EBITDA because 280E means EBITDA converts poorly to free cash. Normalize the tax and that same EBITDA deserves a consumer-products multiple: Constellation Brands trades around 12x EV/EBITDA, and tobacco/CPG peers cluster in the ~10–14x range. Put 10–14x on MariMed's $16.9M of adjusted EBITDA and enterprise value runs $169–237M versus ~$113M today. Here's the amplifier — and the warning. Because MariMed carries ~$75–85M of net debt under a ~$30M equity, the equity is a thin sliver on top of the enterprise value. An EV re-rating to $169–237M, net of debt, implies an equity value of roughly $90–155M — three to five times today's market cap. That leverage is precisely why a seven-cent stock can move violently on a catalyst. It cuts both ways: the same math that triples the equity on good news halves it on bad.
The takeaway isn't a number — it's the shape. At today's price the market is paying for a levered, taxed-to-death microcap and pricing in essentially none of the broad-rescheduling optionality. That optionality is real but contingent, and the downside is equally real because of the debt and the ~$30M bill. Two structural supports temper the downside: MariMed owns most of its real estate (the leverage is mortgages against hard assets, not unsecured cash-flow debt), and a recent Series B preferred refinancing pushed the weighted-average debt maturity to ~4.6 years with no material near-term maturities — which is why management argues the equity is "significantly undervalued" against the asset base. We'd put it more cautiously: the real estate is a genuine backstop, but the ~$30M tax claim still sits ahead of equity holders.
6. Risks and Open Questions
The risks here are unusually concrete. (1) The tax bomb. The accrued, current, and unpaid 280E liability — ~$29.6M as of Q1 FY2026 and still growing — is roughly 4x the company's $7.9M cash and more than half its equity. MariMed is under IRS audit for 2022, and the IRS has stated refund/exemption claims aren't valid; an adverse resolution forces payment MariMed cannot easily fund without dilution or asset sales. (2) Catalyst is partial and contested. The relief that's law is medical-only, and MariMed is ~80% adult-use — it needs the broad order, which faces a stacked DEA hearing (opponents-only, starting June 29, 2026) and a pending D.C. Circuit stay. The catalyst could stall for years. (3) Operating erosion. Operating income has fallen four years running into a 2025 operating loss; wholesale-heavy revenue (44%) is exposed to ongoing price compression. (4) Leverage and liquidity — but no debt wall. ~$79M of total debt (Q1 FY2026; mortgages, notes and leases), a current ratio near 1.0, interest at 4.7% of revenue, and only $7.9M of cash leave little margin for error, and the positive free cash flow partly depends on not paying the tax. The important mitigant, which management corroborated on the Q1 call: the debt is long-dated, not a refinancing time bomb — only ~$2.6M matures in 2026 and roughly 75% ($57.5M) comes due after 2030, anchored by a ten-year, 8.43% real-estate mortgage, and a recent Series B preferred refinancing (with Navy Capital) extended the weighted-average maturity to ~4.6 years. So the near-term survival question is the ~$30M tax bill, not a maturity wall. (5) Microcap, OTC, no analyst coverage — thin liquidity, ~397M shares, and dilution risk if cash gets tight.
7. The Bottom Line
MariMed is the cleanest illustration in the sector of a single idea: 280E doesn't just tax cannabis profits, it manufactures cannabis losses. Strip the tax code away and you have a twenty-five-quarter, positive-EBITDA brand house with the #1 edible in four states, generating cash, trading at 0.7x sales. Leave the tax code in and you have a company that's been charged $27M on four years of breakeven pretax results, that stopped paying, and that now carries a ~$30M back-tax liability larger than its market cap while the IRS audits it. The framework for watching this name is simple. The status quo is roughly priced in. The medical-only relief already on the books does little for an 80%-adult-use operator. The whole equation turns on the broad switch — and on how the 280E dispute resolves, a fight MariMed says it will carry through the administrative process and, if necessary, into Tax Court. What to watch next: the first medical-relief benefit hitting the Q2 FY2026 tax line, the June 29 DEA rescheduling hearing, and any resolution of the 2022 IRS audit. If it breaks MariMed's way, a levered seven-cent microcap re-rates hard; if it breaks the other way, the same leverage works in reverse. That's the trade-off. We're not telling you which way it goes — we're showing you the math so you can decide.
This analysis was built with RoboSystems — open-source, direct access to structured SEC filing data for every public company. New customers get 50% off your first month with code CANNABIS50. robosystems.ai